SynthesisJNCI cancer spectrum2024
Cannabis use among cancer patients and survivors in the United States: a systematic review.
Synthesis in JNCI cancer spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Cannabis use among cancer survivors: a systematic review and meta-analysis.Archives of public health = Archives belges de sante publique · 2026Pooled it
- Cannabis use and perceptions among rural and urban cancer patients and survivors from a Pennsylvania cancer center.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Post-diagnosis cannabis use and its association with health status and quality of life in cancer survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Health Behaviors in Adolescent and Young Adult (AYA) Childhood Cancer Survivors: Prevalence, Determinants, and Comparison With Population Controls.Cancer medicine · 2026Article
- Classic psychedelic and cannabis use among U.S. cancer survivors aged ≥ 50 years: nationally representative estimates by cancer type/site.Cancer causes & control : CCC · 2026Article
- The effects of tetrahydrocannabinol and cannabidiol on sleep in cancer patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Does Cannabinoid Use Reduce Opioid Utilization Among Patients with Gastrointestinal Cancer? Evidence from Epic COSMOS.Cancers · 2026Article
- Review
- Article
- Cannabis Use Among Adolescents and Young Adults with Cancer: A Scoping Review.Journal of cancer education : the official journal of the American Association for Cancer Education · 2025Review
- Cannabis in Hematology Survey Study (CHESS): A Longitudinal Investigation on Uses, Attitudes, and Outcomes of Cannabis Among Hematology Patients Undergoing Hematopoietic Stem Cell Transplant.International journal of environmental research and public health · 2025Article
- Prevalence and determinants of cigarette-cannabis co-use among US cancer survivors.Journal of cancer survivorship : research and practice · 2025Article
- Multifaced roles of cannabinoid therapy in cancer: balancing analgesia, antitumor potential, and systemic toxicity.Frontiers in pharmacology · 2025Article
- Research mapping of cannabinoids and endocannabinoid system in cancer over the past three decades: insights from bibliometric analysis.Frontiers in pharmacology · 2025Article
- Review
- Cannabis Use Among Cancer Patients During Active Treatment: Findings From a Study at an NCI-Designated Cancer Center.Cancer medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundHow cannabis products are being used by cancer patients and survivors in the United States is poorly understood. This study reviewed observational data to understand the modes, patterns, reasons, discontinuation, and adverse experiences of cannabis use.
methodsPubMed and PsycINFO database searches were conducted between May 2022 and November 2022. Of the 1162 studies identified, 27 studies met the inclusion criteria. The intercoder agreement was strong (0.81).
resultsThe majority (74%) of the studies were cross-sectional in design. Study samples were approximately equal proportions of men and women and majority White participants. The prevalence of cannabis use based on national samples ranged between 4.8% and 22%. The most common modes of cannabis intake were topical application (80%), smoking (73%), vaping (12%), and ingestion of edible products (10%). Younger age, male gender, being a current or former smoker, and higher socioeconomic status were associated with greater likelihood of cannabis use. The main motive for cannabis use was management of symptoms due to cancer or cancer treatment such as pain, nausea, lack of sleep, and anxiety. A majority of the participants across studies reported that cannabis helped reduce these symptoms. Lack of symptom improvement, side effects such as fatigue and paranoia, cost, and social stigma were identified as some of the reasons for discontinuing cannabis use.
conclusionsIt appears that cannabis may help cancer patients and survivors manage symptoms. However, more longitudinal studies are needed to determine whether positive experiences of cannabis use outweigh adverse experiences over time in this vulnerable population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.